Insider Trading Activity Nabriva Therapeutics (NASDAQ:NBRV) – General Counsel Bought 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Nabriva Therapeutics (NASDAQ:NBRV)

Robert Crotty , General Counsel of Nabriva Therapeutics (NASDAQ:NBRV) reportedly Bought 10,000 shares of the company’s stock at an average price of 4.48 for a total transaction amount of $44,800.00 SEC Form

Insider Trading History For Nabriva Therapeutics (NASDAQ:NBRV)

  • On 4/10/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 90,594 with an average share price of $10.96 per share and the total transaction amounting to $992,910.24.
  • On 4/13/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 32,831 with an average share price of $11.24 per share and the total transaction amounting to $369,020.44.
  • On 4/20/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 23,932 with an average share price of $11.11 per share and the total transaction amounting to $265,884.52.
  • On 4/21/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 2,622 with an average share price of $11.04 per share and the total transaction amounting to $28,946.88.
  • On 4/28/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 15,939 with an average share price of $11.02 per share and the total transaction amounting to $175,647.78.
  • On 5/15/2017 George Harrison Talbot, Director, sold 50 with an average share price of $101.50 per share and the total transaction amounting to $5,075.00.
  • On 5/16/2017 George Harrison Talbot, Director, sold 200 with an average share price of $102.44 per share and the total transaction amounting to $20,488.00.

    • Analyst Ratings History For Nabriva Therapeutics (NASDAQ:NBRV)

    • On 12/20/2016 Royal Bank of Canada Set Price Target of rating Buy with a price target of $22.00
    • On 9/18/2017 SunTrust Banks Boost Price Target of rating Buy with a price target of $20.00 ➝ $24.00
    • On 9/18/2017 Leerink Swann Reiterated Rating Outperform with a price target of $20.00 ➝ $22.00
    • On 11/16/2017 HC Wainwright Reiterated Rating Buy with a price target of $20.00
    • On 1/17/2018 Morgan Stanley Initiated Coverage of rating Overweight ➝ Overweight with a price target of $10.00
    • On 3/19/2018 Wedbush Reiterated Rating Outperform
    • On 5/8/2018 Needham & Company LLC Reiterated Rating Buy with a price target of $18.00

    Recent Trading Activity for Nabriva Therapeutics (NASDAQ:NBRV)
    Shares of Nabriva Therapeutics closed the previous trading session at 4.58 up +0.03 0.66% with 749326 shares trading hands.